Drug Trial Radar · NCT07407673
Prediction and Prevention of Bloodstream Infections After Kidney Transplantation
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Jan 1, 2027
Primary completion
Jul 2031
Study completion Jul 2041
Sponsor
- Lead sponsor
- Susanne Dam Nielsen, MD, DMScAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Aarhus University Hospital; Odense University Hospital; Zealand University Hospital; Aalborg University Hospital; Copenhagen University Hospital, Rigshospitalet
- First posted
- Feb 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Kidney transplant recipients take medicines that suppress the immune system to prevent rejection of the transplanted kidney. As a result, they have a high risk of infections, especially urinary tract infections (UTIs). Some of these infections can spread to the bloodstream and cause serious illness, hospitalization, loss of kidney function, or death. Currently, there is no established strategy to prevent these serious bacterial infections in kidney transplant recipients who are at highest risk. The PREDICT study is investigating whether a low daily dose of the antibiotic pivmecillinam can reduce the risk of bacterial urinary tract infections and bloodstream infections after kidney transplantation. The study includes kidney transplant recipients who have bacteria detected in their urine during the first month after transplantation, as previous research suggests that these patients have a particularly high risk of developing later serious infections. In this randomized, double-blind, placebo-controlled trial, 180 adult kidney transplant recipients will be assigned by chance to receive either pivmecillinam or a matching placebo from 1 to 6 months after transplantation. Neither participants nor study staff will know which treatment has been assigned during the study. All participants will continue to receive standard post-transplant care and monitoring. The main goal of the study is to determine whether prophylactic pivmecillinam can reduce the occurrence of infections caused by Enterobacterales bacteria, including urinary tract infections and bloodstream infections, during the first 6 months after transplantation. The study will also evaluate the effects of treatment on serious clinical outcomes, safety, quality of life, antimicrobial resistance, and long-term kidney transplant outcomes. The main hypothesis is that targeted antibiotic prophylaxis with pivmecillinam in kidney transplant recipients at increased risk of infection will reduce the incidence of Enterobacterales urinary tract infections and bloodstream infections during the high-risk period after transplantation compared with placebo.
Conditions
- Kidney Transplant Infection
- Bloodstream Infection
- Kidney Transplant
- Kidney Transplant Recipients
- Infection
- Urinary Tract Infection(UTI)
- Urinary Tract Infection Bacterial
- Antibiotic Prophylaxis
- Bacteriuria
Interventions
PivmecillinamDrug
Study participants in the intervention arm will receive 400 mg pivmecillinam tablets once daily administered orally. Treatment will be initiated one month post-transplantation and will continue for a total duration of 5 months (months 1-6 post-transplantation).
PlaceboDrug
Study participants in the placebo arm will receive one inactive placebo tablet once daily; the timing, frequency and duration is the same as for the active study drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Enterobacterales Urinary Tract Infections and/or Enterobacterales Bloodstream InfectionsTime frame: Months 1-6 post-transplantation
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Aarhus University Hospital, Department of Nephrology
Aarhus, Denmark
Rigshospitalet, Department of Nephrology
Copenhagen, Denmark
Odense University Hospital, Department of Nephrology
Odense, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.